Jayson Rieger

Jayson Rieger

Chief Executive Officer at VERRICA PHARMACEUTICALS INC.

Net worth: 1 M $ as of 2026-05-30

50 year
Health Technology
Consumer Services
Finance

Profile

Jayson M.
Rieger
is President, Chief Executive Officer & Director at Verrica Pharmaceuticals, Inc. since 2024.
Dr. Rieger is Director at Xalud Therapeutics, Inc. Dr. Rieger is Managing Partner at PBM Capital Group LLC since 2014.
Formerly, Dr. Rieger was Chief Operating Officer & Director at Verrica Pharmaceuticals, Inc. from 2015 to 2018.
Dr. Rieger was Director at Lytix Biopharma ASA. Dr. Rieger was Senior VP & President-Human Therapeutics at Precigen, Inc. from 2012 to 2013.
Dr. Rieger was Vice President-Research & Virginia Operations at Clinical Data, Inc. from 2008 to 2011.
Dr. Rieger was Vice President-Lead Development & Manufacturing at Adenosine Therapeutics LLC from 2002 to 2008.
Education includes a doctorate from the University of Virginia, an undergraduate degree from Rollins College (Florida), and an MBA from the University of Virginia Darden School of Business.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-06-04 183,298 ( 1.07% ) 1 M $ 2026-05-30

Jayson Rieger active positions

CompaniesPositionStart
VERRICA PHARMACEUTICALS INC. Chief Executive Officer 2024-11-04
Director/Board Member -
Private Equity Investor 2014-02-28

Former positions of Jayson Rieger

CompaniesPositionEnd
VERRICA PHARMACEUTICALS INC. Chief Operating Officer -
PRECIGEN, INC. Corporate Officer/Principal 2013-07-31
Corporate Officer/Principal 2010-12-31
Corporate Officer/Principal 2007-12-31
LYTIX BIOPHARMA ASA Director/Board Member -
See the detail of Jayson Rieger's experience

Training of Jayson Rieger

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

18

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Finance

Consumer Services

Health Technology

Health Technology

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!